1-adamantyl-[(3R)-3-methyl-4-pyrazin-2-ylpiperazin-1-yl]methanone | 1443748-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-adamantyl-[(3R)-3-methyl-4-pyrazin-2-ylpiperazin-1-yl]methanone
• CAS: 1443748-37-5
• 化学式: C₂₀H₂₈N₄O
• 分子量: 340.469
• InChiKey: PTMVKKWRNWVHAY-ZIUDEIKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (R)-1-N-Boc-2-甲基哌嗪 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 0.17h， 生成 1-adamantyl-[(3R)-3-methyl-4-pyrazin-2-ylpiperazin-1-yl]methanone
  参考文献：
  名称：

  N-Acyl-N′-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats

  摘要：

  Development of SAR in an N-acyl-N'-arylpiperazine series of negative allosteric modulators of mGlu(1) using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.020

文献信息

• N-Acyl-N′-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats
  作者：Kimberly M. Lovell、Andrew S. Felts、Alice L. Rodriguez、Daryl F. Venable、Hyekyung P. Cho、Ryan D. Morrison、Frank W. Byers、J. Scott Daniels、Colleen M. Niswender、P. Jeffrey Conn、Craig W. Lindsley、Kyle A. Emmitte

  DOI：10.1016/j.bmcl.2013.05.020

  日期：2013.7

  Development of SAR in an N-acyl-N'-arylpiperazine series of negative allosteric modulators of mGlu(1) using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats. (C) 2013 Elsevier Ltd. All rights reserved.